Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5311911 | 0.99 | VDR (0.39) | VDRLMNAARKIF11SLC1A3 | |
| SCHEMBL29391622 | 0.86 | VDR (0.38) | VDRLMNAARKIF11SLC1A3 | |
| SCHEMBL5311924 | 0.86 | VDR (0.38) | VDRLMNAARKIF11SLC1A3 | |
| SCHEMBL5313148 | 0.82 | VDR (0.41) | VDRLMNAARKIF11SLC1A3 | |
| SCHEMBL5311847 | 0.80 | CA1 (0.32) | LMNA | |
| SCHEMBL19834217 | 0.79 | HTT (0.54) | LMNASMN1; SMN2HTT | |
| SCHEMBL9762950 | 0.77 | GAA (0.43) | LMNASMN1; SMN2HTT | |
| SCHEMBL5509688 | 0.75 | MET (0.32) | MET | |
| SCHEMBL5314416 | 0.75 | KIF11 (0.39) | VDRLMNAARKIF11SLC1A3 | |
| SCHEMBL574676 | 0.74 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020257930-A1 | STABLE ALKYL BENZIDINE COMPOSITION AND METHODS OF MAKING AND USING SAME | OneStep Technologies Inc. (CA) | 2020-12-30 | — | — | WO | claimed |
| US-10597352-B1 | Stable alkyl benzidine composition and methods of making and using same | OneStep Technologies Inc. (CA) | 2020-03-24 | — | — | US | claimed |
| WO-2020257930-A1 | STABLE ALKYL BENZIDINE COMPOSITION AND METHODS OF MAKING AND USING SAME | OneStep Technologies Inc. (CA) | 2020-12-30 | — | — | WO | disclosed |
| US-10597352-B1 | Stable alkyl benzidine composition and methods of making and using same | OneStep Technologies Inc. (CA) | 2020-03-24 | — | — | US | disclosed |
| US-10585079-B2 | Chlorine-concentration-measuring composition | KURITA WATER INDUSTRIES LTD. (JP) | 2020-03-10 | — | — | US | disclosed |
| US-20160377583-A1 | CHLORINE-CONCENTRATION-MEASURING COMPOSITION | KURITA WATER INDUSTRIES LTD. (JP) | 2016-12-29 | — | — | US | disclosed |
| US-20070224691-A1 | Composition for measuring concentration of residual chlorine | MIURA CO., LTD. | 2007-09-27 | — | — | US | disclosed |
| EP-1837653-A1 | Composition for measuring concentration of residual chlorine | MIURA CO., LTD. (JP) | 2007-09-26 | — | — | EP | disclosed |
| EP-1770394-A2 | Composition for measuring residual chlorine concentration | MIURA CO., LTD. (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-20070072305-A1 | Composition for measuring residual chlorine concentration | MIURA CO., LTD. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597352-B1 | Stable alkyl benzidine composition and methods of making and using same | C9, BBC3, CTRC | VDR 1285/4885LMNA 1723/4885AR 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.